The global Peripherally Acting Anti-Obesity Drug market was valued at million in 2024 and is projected to reach US$ million by 2031, at a CAGR of %during the forecast period.
A Peripherally Acting Anti-Obesity Drug is a medication designed to treat obesity by acting on the peripheral nervous system or other systems in the body. These drugs target various mechanisms involved in appetite regulation, metabolism, and fat absorption to aid in weight loss.
The U.S. market size is estimated at $ million in 2024, while China is to reach $ million.
Prescription Drugs segment will reach $ million by 2031, with a % CAGR in next six years.
The global key manufacturers of Peripherally Acting Anti-Obesity Drug include Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc., Gelesis Holdings, Vivus LLC., Currax Pharmaceuticals LLC, GlaxoSmithKline plc, CHEPLAPHARM Arzneimittel GmbH, Rhythm Pharmaceuticals, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Peripherally Acting Anti-Obesity Drug manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Peripherally Acting Anti-Obesity Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripherally Acting Anti-Obesity Drug. This report contains market size and forecasts of Peripherally Acting Anti-Obesity Drug in global, including the following market information:
Global Peripherally Acting Anti-Obesity Drug market revenue, 2020-2025, 2026-2031, ($ millions)
Global Peripherally Acting Anti-Obesity Drug market sales, 2020-2025, 2026-2031, (K Units)
Global top five Peripherally Acting Anti-Obesity Drug companies in 2024 (%)
Total Market by Segment:
Global Peripherally Acting Anti-Obesity Drug market, by Type, 2020-2025, 2026-2031 ($ millions) & (K Units)
Global Peripherally Acting Anti-Obesity Drug market segment percentages, by Type, 2024 (%)
Prescription Drugs
Non-prescription Drugs
Global Peripherally Acting Anti-Obesity Drug market, by Application, 2020-2025, 2026-2031 ($ Millions) & (K Units)
Global Peripherally Acting Anti-Obesity Drug market segment percentages, by Application, 2024 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Peripherally Acting Anti-Obesity Drug market, by region and country, 2020-2025, 2026-2031 ($ millions) & (K Units)
Global Peripherally Acting Anti-Obesity Drug market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peripherally Acting Anti-Obesity Drug revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Peripherally Acting Anti-Obesity Drug revenues share in global market, 2024 (%)
Key companies Peripherally Acting Anti-Obesity Drug sales in global market, 2020-2025 (estimated), (K Units)
Key companies Peripherally Acting Anti-Obesity Drug sales share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk A/S
Pfizer Inc.
Boehringer Ingelheim International GmbH
KVK Tech Inc.
Gelesis Holdings
Vivus LLC.
Currax Pharmaceuticals LLC
GlaxoSmithKline plc
CHEPLAPHARM Arzneimittel GmbH
Rhythm Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Peripherally Acting Anti-Obesity Drug, market overview.
Chapter 2: Global Peripherally Acting Anti-Obesity Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peripherally Acting Anti-Obesity Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Peripherally Acting Anti-Obesity Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Peripherally Acting Anti-Obesity Drug Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Peripherally Acting Anti-Obesity Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Peripherally Acting Anti-Obesity Drug Overall Market Size
2.1 Global Peripherally Acting Anti-Obesity Drug Market Size: 2024 VS 2031
2.2 Global Peripherally Acting Anti-Obesity Drug Market Size, Prospects & Forecasts: 2020-2031
2.3 Global Peripherally Acting Anti-Obesity Drug Sales: 2020-2031
3 Company Landscape
3.1 Top Peripherally Acting Anti-Obesity Drug Players in Global Market
3.2 Top Global Peripherally Acting Anti-Obesity Drug Companies Ranked by Revenue
3.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Companies
3.4 Global Peripherally Acting Anti-Obesity Drug Sales by Companies
3.5 Global Peripherally Acting Anti-Obesity Drug Price by Manufacturer (2020-2025)
3.6 Top 3 and Top 5 Peripherally Acting Anti-Obesity Drug Companies in Global Market, by Revenue in 2024
3.7 Global Manufacturers Peripherally Acting Anti-Obesity Drug Product Type
3.8 Tier 1, Tier 2, and Tier 3 Peripherally Acting Anti-Obesity Drug Players in Global Market
3.8.1 List of Global Tier 1 Peripherally Acting Anti-Obesity Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Peripherally Acting Anti-Obesity Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Market Size Markets, 2024 & 2031
4.1.2 Prescription Drugs
4.1.3 Non-prescription Drugs
4.2 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue & Forecasts
4.2.1 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue, 2020-2025
4.2.2 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue, 2026-2031
4.2.3 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
4.3 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales & Forecasts
4.3.1 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales, 2020-2025
4.3.2 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales, 2026-2031
4.3.3 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
4.4 Segment by Type - Global Peripherally Acting Anti-Obesity Drug Price (Manufacturers Selling Prices), 2020-2031
5 Sights by Application
5.1 Overview
5.1.1 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Market Size, 2024 & 2031
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue & Forecasts
5.2.1 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue, 2020-2025
5.2.2 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue, 2026-2031
5.2.3 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
5.3 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales & Forecasts
5.3.1 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales, 2020-2025
5.3.2 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales, 2026-2031
5.3.3 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
5.4 Segment by Application - Global Peripherally Acting Anti-Obesity Drug Price (Manufacturers Selling Prices), 2020-2031
6 Sights by Region
6.1 By Region - Global Peripherally Acting Anti-Obesity Drug Market Size, 2024 & 2031
6.2 By Region - Global Peripherally Acting Anti-Obesity Drug Revenue & Forecasts
6.2.1 By Region - Global Peripherally Acting Anti-Obesity Drug Revenue, 2020-2025
6.2.2 By Region - Global Peripherally Acting Anti-Obesity Drug Revenue, 2026-2031
6.2.3 By Region - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
6.3 By Region - Global Peripherally Acting Anti-Obesity Drug Sales & Forecasts
6.3.1 By Region - Global Peripherally Acting Anti-Obesity Drug Sales, 2020-2025
6.3.2 By Region - Global Peripherally Acting Anti-Obesity Drug Sales, 2026-2031
6.3.3 By Region - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
6.4 North America
6.4.1 By Country - North America Peripherally Acting Anti-Obesity Drug Revenue, 2020-2031
6.4.2 By Country - North America Peripherally Acting Anti-Obesity Drug Sales, 2020-2031
6.4.3 United States Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.4.4 Canada Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.4.5 Mexico Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5 Europe
6.5.1 By Country - Europe Peripherally Acting Anti-Obesity Drug Revenue, 2020-2031
6.5.2 By Country - Europe Peripherally Acting Anti-Obesity Drug Sales, 2020-2031
6.5.3 Germany Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.4 France Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.5 U.K. Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.6 Italy Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.7 Russia Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.8 Nordic Countries Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.5.9 Benelux Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.6 Asia
6.6.1 By Region - Asia Peripherally Acting Anti-Obesity Drug Revenue, 2020-2031
6.6.2 By Region - Asia Peripherally Acting Anti-Obesity Drug Sales, 2020-2031
6.6.3 China Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.6.4 Japan Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.6.5 South Korea Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.6.6 Southeast Asia Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.6.7 India Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.7 South America
6.7.1 By Country - South America Peripherally Acting Anti-Obesity Drug Revenue, 2020-2031
6.7.2 By Country - South America Peripherally Acting Anti-Obesity Drug Sales, 2020-2031
6.7.3 Brazil Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.7.4 Argentina Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue, 2020-2031
6.8.2 By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales, 2020-2031
6.8.3 Turkey Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.8.4 Israel Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.8.5 Saudi Arabia Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
6.8.6 UAE Peripherally Acting Anti-Obesity Drug Market Size, 2020-2031
7 Manufacturers & Brands Profiles
7.1 Novo Nordisk A/S
7.1.1 Novo Nordisk A/S Company Summary
7.1.2 Novo Nordisk A/S Business Overview
7.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.1.5 Novo Nordisk A/S Key News & Latest Developments
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Company Summary
7.2.2 Pfizer Inc. Business Overview
7.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.2.5 Pfizer Inc. Key News & Latest Developments
7.3 Boehringer Ingelheim International GmbH
7.3.1 Boehringer Ingelheim International GmbH Company Summary
7.3.2 Boehringer Ingelheim International GmbH Business Overview
7.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.3.5 Boehringer Ingelheim International GmbH Key News & Latest Developments
7.4 KVK Tech Inc.
7.4.1 KVK Tech Inc. Company Summary
7.4.2 KVK Tech Inc. Business Overview
7.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.4.5 KVK Tech Inc. Key News & Latest Developments
7.5 Gelesis Holdings
7.5.1 Gelesis Holdings Company Summary
7.5.2 Gelesis Holdings Business Overview
7.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.5.5 Gelesis Holdings Key News & Latest Developments
7.6 Vivus LLC.
7.6.1 Vivus LLC. Company Summary
7.6.2 Vivus LLC. Business Overview
7.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.6.5 Vivus LLC. Key News & Latest Developments
7.7 Currax Pharmaceuticals LLC
7.7.1 Currax Pharmaceuticals LLC Company Summary
7.7.2 Currax Pharmaceuticals LLC Business Overview
7.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.7.5 Currax Pharmaceuticals LLC Key News & Latest Developments
7.8 GlaxoSmithKline plc
7.8.1 GlaxoSmithKline plc Company Summary
7.8.2 GlaxoSmithKline plc Business Overview
7.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.8.5 GlaxoSmithKline plc Key News & Latest Developments
7.9 CHEPLAPHARM Arzneimittel GmbH
7.9.1 CHEPLAPHARM Arzneimittel GmbH Company Summary
7.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
7.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.9.5 CHEPLAPHARM Arzneimittel GmbH Key News & Latest Developments
7.10 Rhythm Pharmaceuticals
7.10.1 Rhythm Pharmaceuticals Company Summary
7.10.2 Rhythm Pharmaceuticals Business Overview
7.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Major Product Offerings
7.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales and Revenue in Global (2020-2025)
7.10.5 Rhythm Pharmaceuticals Key News & Latest Developments
8 Global Peripherally Acting Anti-Obesity Drug Production Capacity, Analysis
8.1 Global Peripherally Acting Anti-Obesity Drug Production Capacity, 2020-2031
8.2 Peripherally Acting Anti-Obesity Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Peripherally Acting Anti-Obesity Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Peripherally Acting Anti-Obesity Drug Supply Chain Analysis
10.1 Peripherally Acting Anti-Obesity Drug Industry Value Chain
10.2 Peripherally Acting Anti-Obesity Drug Upstream Market
10.3 Peripherally Acting Anti-Obesity Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Peripherally Acting Anti-Obesity Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
List of Tables
Table 1. Key Players of Peripherally Acting Anti-Obesity Drug in Global Market
Table 2. Top Peripherally Acting Anti-Obesity Drug Players in Global Market, Ranking by Revenue (2024)
Table 3. Global Peripherally Acting Anti-Obesity Drug Revenue by Companies, (US$, Mn), 2020-2025
Table 4. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Companies, 2020-2025
Table 5. Global Peripherally Acting Anti-Obesity Drug Sales by Companies, (K Units), 2020-2025
Table 6. Global Peripherally Acting Anti-Obesity Drug Sales Share by Companies, 2020-2025
Table 7. Key Manufacturers Peripherally Acting Anti-Obesity Drug Price (2020-2025) & (US$/Unit)
Table 8. Global Manufacturers Peripherally Acting Anti-Obesity Drug Product Type
Table 9. List of Global Tier 1 Peripherally Acting Anti-Obesity Drug Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Peripherally Acting Anti-Obesity Drug Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segment by Type – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2024 & 2031
Table 12. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue (US$, Mn), 2020-2025
Table 13. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue (US$, Mn), 2026-2031
Table 14. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales (K Units), 2020-2025
Table 15. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales (K Units), 2026-2031
Table 16. Segment by Application – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2024 & 2031
Table 17. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 18. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 19. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 20. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 21. By Region – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2025-2031
Table 22. By Region - Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 23. By Region - Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 24. By Region - Global Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 25. By Region - Global Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 26. By Country - North America Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 27. By Country - North America Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 28. By Country - North America Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 29. By Country - North America Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 30. By Country - Europe Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 31. By Country - Europe Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 32. By Country - Europe Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 33. By Country - Europe Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 34. By Region - Asia Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 35. By Region - Asia Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 36. By Region - Asia Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 37. By Region - Asia Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 38. By Country - South America Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 39. By Country - South America Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 40. By Country - South America Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 41. By Country - South America Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 42. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2025
Table 43. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2026-2031
Table 44. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2020-2025
Table 45. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales, (K Units), 2026-2031
Table 46. Novo Nordisk A/S Company Summary
Table 47. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Offerings
Table 48. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 49. Novo Nordisk A/S Key News & Latest Developments
Table 50. Pfizer Inc. Company Summary
Table 51. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Offerings
Table 52. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 53. Pfizer Inc. Key News & Latest Developments
Table 54. Boehringer Ingelheim International GmbH Company Summary
Table 55. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Offerings
Table 56. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 57. Boehringer Ingelheim International GmbH Key News & Latest Developments
Table 58. KVK Tech Inc. Company Summary
Table 59. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Offerings
Table 60. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 61. KVK Tech Inc. Key News & Latest Developments
Table 62. Gelesis Holdings Company Summary
Table 63. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Offerings
Table 64. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 65. Gelesis Holdings Key News & Latest Developments
Table 66. Vivus LLC. Company Summary
Table 67. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Offerings
Table 68. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 69. Vivus LLC. Key News & Latest Developments
Table 70. Currax Pharmaceuticals LLC Company Summary
Table 71. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Offerings
Table 72. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 73. Currax Pharmaceuticals LLC Key News & Latest Developments
Table 74. GlaxoSmithKline plc Company Summary
Table 75. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Offerings
Table 76. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 77. GlaxoSmithKline plc Key News & Latest Developments
Table 78. CHEPLAPHARM Arzneimittel GmbH Company Summary
Table 79. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Offerings
Table 80. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 81. CHEPLAPHARM Arzneimittel GmbH Key News & Latest Developments
Table 82. Rhythm Pharmaceuticals Company Summary
Table 83. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Offerings
Table 84. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 85. Rhythm Pharmaceuticals Key News & Latest Developments
Table 86. Peripherally Acting Anti-Obesity Drug Capacity of Key Manufacturers in Global Market, 2023-2025 (K Units)
Table 87. Global Peripherally Acting Anti-Obesity Drug Capacity Market Share of Key Manufacturers, 2023-2025
Table 88. Global Peripherally Acting Anti-Obesity Drug Production by Region, 2020-2025 (K Units)
Table 89. Global Peripherally Acting Anti-Obesity Drug Production by Region, 2026-2031 (K Units)
Table 90. Peripherally Acting Anti-Obesity Drug Market Opportunities & Trends in Global Market
Table 91. Peripherally Acting Anti-Obesity Drug Market Drivers in Global Market
Table 92. Peripherally Acting Anti-Obesity Drug Market Restraints in Global Market
Table 93. Peripherally Acting Anti-Obesity Drug Raw Materials
Table 94. Peripherally Acting Anti-Obesity Drug Raw Materials Suppliers in Global Market
Table 95. Typical Peripherally Acting Anti-Obesity Drug Downstream
Table 96. Peripherally Acting Anti-Obesity Drug Downstream Clients in Global Market
Table 97. Peripherally Acting Anti-Obesity Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Peripherally Acting Anti-Obesity Drug Product Picture
Figure 2. Peripherally Acting Anti-Obesity Drug Segment by Type in 2024
Figure 3. Peripherally Acting Anti-Obesity Drug Segment by Application in 2024
Figure 4. Global Peripherally Acting Anti-Obesity Drug Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Peripherally Acting Anti-Obesity Drug Market Size: 2024 VS 2031 (US$, Mn)
Figure 7. Global Peripherally Acting Anti-Obesity Drug Revenue: 2020-2031 (US$, Mn)
Figure 8. Peripherally Acting Anti-Obesity Drug Sales in Global Market: 2020-2031 (K Units)
Figure 9. The Top 3 and 5 Players Market Share by Peripherally Acting Anti-Obesity Drug Revenue in 2024
Figure 10. Segment by Type – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2024 & 2031
Figure 11. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 12. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 13. Segment by Type - Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit), 2020-2031
Figure 14. Segment by Application – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2024 & 2031
Figure 15. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 16. Segment by Application - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 17. Segment by Application -Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit), 2020-2031
Figure 18. By Region – Global Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2025 & 2031
Figure 19. By Region - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020 VS 2024 VS 2031
Figure 20. By Region - Global Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 21. By Region - Global Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 22. By Country - North America Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 23. By Country - North America Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 24. United States Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 25. Canada Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 26. Mexico Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 27. By Country - Europe Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 28. By Country - Europe Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 29. Germany Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 30. France Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 31. U.K. Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 32. Italy Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 33. Russia Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 34. Nordic Countries Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 35. Benelux Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 36. By Region - Asia Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 37. By Region - Asia Peripherally Acting Anti-Obesity Drug Sales Market Share, 2020-2031
Figure 38. China Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 39. Japan Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 40. South Korea Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 41. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 42. India Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 43. By Country - South America Peripherally Acting Anti-Obesity Drug Revenue Market Share, 2020-2031
Figure 44. By Country - South America Peripherally Acting Anti-Obesity Drug Sales, Market Share, 2020-2031
Figure 45. Brazil Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 46. Argentina Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 47. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue, Market Share, 2020-2031
Figure 48. By Country - Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales, Market Share, 2020-2031
Figure 49. Turkey Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 50. Israel Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 51. Saudi Arabia Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 52. UAE Peripherally Acting Anti-Obesity Drug Revenue, (US$, Mn), 2020-2031
Figure 53. Global Peripherally Acting Anti-Obesity Drug Production Capacity (K Units), 2020-2031
Figure 54. The Percentage of Production Peripherally Acting Anti-Obesity Drug by Region, 2024 VS 2031
Figure 55. Peripherally Acting Anti-Obesity Drug Industry Value Chain
Figure 56. Marketing Channels
